View Filing Data

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2018	Aug. 03, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q2
Trading Symbol	OSUR
Entity Registrant Name	ORASURE TECHNOLOGIES INC
Entity Central Index Key	0001116463
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		61,173,523

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
CURRENT ASSETS:
Cash and cash equivalents	$ 71,047	$ 71,029
Restricted cash	22	1,840
Short-term investments	74,269	83,028
Accounts receivable, net of allowance for doubtful accounts of $301 and $471	31,648	42,521
Inventories	20,599	19,343
Prepaid expenses	1,519	1,658
Other current assets	3,118	2,486
Total current assets	202,222	221,905
PROPERTY AND EQUIPMENT, net	23,946	21,372
INTANGIBLE ASSETS, net	6,622	8,223
GOODWILL	19,231	20,083
LONG TERM INVESTMENTS	35,828	20,690
OTHER ASSETS	4,513	3,928
TOTAL ASSETS	292,362	296,201
CURRENT LIABILITIES:
Accounts payable	9,659	10,228
Deferred revenue	1,621	1,314
Accrued expenses	9,837	20,695
Total current liabilities	21,117	32,237
OTHER LIABILITIES	4,474	3,932
DEFERRED INCOME TAXES	1,600	1,951
COMMITMENTS AND CONTINGENCIES (Note 8)
STOCKHOLDERS' EQUITY
Preferred stock, par value $.000001, 25,000 shares authorized, none issued
Common stock, par value $.000001, 120,000 shares authorized, 61,174 and 60,662 shares issued and outstanding	0	0
Additional paid-in capital	397,218	387,931
Accumulated other comprehensive loss	(14,464)	(10,340)
Accumulated deficit	(117,583)	(119,510)
Total stockholders' equity	265,171	258,081
Total liabilities and stockholders' equity	$ 292,362	$ 296,201

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Statement Of Financial Position [Abstract]
Allowance for doubtful accounts	$ 301	$ 471
Preferred stock, par value	$ 0.000001	$ 0.000001
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.000001	$ 0.000001
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	61,174,000	60,662,000
Common stock, shares outstanding	61,174,000	60,662,000

Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
NET REVENUES:
Total revenue	$ 43,625	$ 40,176	$ 85,612	$ 72,722
COST OF PRODUCTS SOLD	17,730	14,699	35,250	26,935
Gross profit	25,895	25,477	50,362	45,787
OPERATING EXPENSES:
Research and development	4,261	3,338	8,336	6,308
Sales and marketing	7,429	7,502	14,928	14,379
General and administrative	8,647	7,750	22,038	14,842
Gain on litigation settlement				(12,500)
Total operating expenses	20,337	18,590	45,302	23,029
Operating income	5,558	6,887	5,060	22,758
OTHER INCOME	736	96	1,148	563
Income before income taxes	6,294	6,983	6,208	23,321
INCOME TAX EXPENSE	2,173	1,555	4,206	5,452
NET INCOME	$ 4,121	$ 5,428	$ 2,002	$ 17,869
EARNINGS PER SHARE:
BASIC	$ 0.07	$ 0.09	$ 0.03	$ 0.31
DILUTED	$ 0.07	$ 0.09	$ 0.03	$ 0.30
SHARES USED IN COMPUTING EARNINGS PER SHARE:
BASIC	61,100	58,478	60,983	57,708
DILUTED	62,244	60,728	62,379	59,755
Product [Member]
NET REVENUES:
Total revenue	$ 38,818	$ 39,132	$ 77,136	$ 70,614
Other Revenues [Member]
NET REVENUES:
Total revenue	$ 4,807	$ 1,044	$ 8,476	$ 2,108

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Statement Of Income And Comprehensive Income [Abstract]
NET INCOME	$ 4,121	$ 5,428	$ 2,002	$ 17,869
OTHER COMPREHENSIVE INCOME (LOSS)
Currency translation adjustments	(1,652)	1,862	(3,806)	2,312
Unrealized gain (loss) on marketable securities	194	(55)	(318)	(55)
COMPREHENSIVE INCOME (LOSS)	$ 2,663	$ 7,235	$ (2,122)	$ 20,126

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
OPERATING ACTIVITIES:
Net income	$ 2,002	$ 17,869
Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation	11,262	3,631
Depreciation and amortization	3,746	2,891
Unrealized foreign currency (gain) loss	(255)	178
Deferred income taxes	(272)	(322)
Changes in assets and liabilities
Accounts receivable	10,166	(6,923)
Inventories	(1,429)	(2,680)
Prepaid expenses and other assets	289	1,525
Accounts payable	(193)	4,739
Deferred revenue	253	83
Accrued expenses and other liabilities	(11,641)	713
Net cash provided by operating activities	13,928	21,704
INVESTING ACTIVITIES:
Purchases of investments	(93,917)	(62,233)
Proceeds from maturities and redemptions of investments	85,926	18,585
Purchases of property and equipment	(4,484)	(1,567)
Net cash (used in) investing activities	(12,475)	(45,215)
FINANCING ACTIVITIES:
Proceeds from exercise of stock options	1,201	21,014
Repurchase of common stock	(3,171)	(1,209)
Net cash (used in) provided by financing activities	(1,970)	19,805
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH	(1,283)	619
NET (DECREASE) IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH	(1,800)	(3,087)
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, BEGINNING OF PERIOD	72,869	109,790
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, END OF PERIOD	71,069	106,703
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for income taxes	11,159	4,325
Noncash investing activities (accrued property and equipment purchases)	665	$ 412
Noncash unrealized losses on marketable securities	$ (318)

The Company

6 Months Ended

Jun. 30, 2018

Organization Consolidation And Presentation Of Financial Statements [Abstract]

The Company

1.	The Company

Our business is comprised of two segments: our “OSUR” business consists of the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using our proprietary technologies, as well as other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Our molecular collections systems or “DNAG” business consists of the manufacture and sale of specimen collection kits that are used to collect, stabilize, transport and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome and animal genetics markets.

Our OSUR diagnostic products include tests that are performed on a rapid basis at the point of care and tests that are processed in a laboratory. These products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. We also manufacture and sell medical devices used for the removal of benign skin lesions by cryosurgery or freezing. These cryosurgical products are sold in both professional and over-the-counter (“OTC”) markets in North America, Europe, Central and South America, and Australia.

Our “DNAG” or molecular collection systems business is operated by our subsidiary, DNA Genotek Inc., a company based in Ottawa, Canada. DNAG’s Oragene^® DNA sample collection kit provides an all-in-one system for the collection, stabilization, transportation and storage of DNA from human saliva. We also sell research use only sample collection products into the microbiome and tuberculosis markets and we offer our customers a suite of genomics and microbiome services called “GenoFIND^TM”, which range from package customization and study design optimization to extraction, analysis and reporting services. We serve customers worldwide, including many leading research universities and hospitals.

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2018

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2.	Summary of Significant Accounting Policies

Principles of Consolidation and Basis of Presentation. The consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiary, DNA Genotek Inc. (“DNAG”). All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiary, unless otherwise indicated.

The accompanying consolidated financial statements are unaudited and, in the opinion of management, include all adjustments (consisting only of normal and recurring adjustments) necessary for a fair presentation of our financial position and results of operations for these interim periods. These financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017. Results of operations for the three and six months ended June 30, 2018 are not necessarily indicative of the results of operations expected for the full year.

Use of Estimates. The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to accruals, taxes, and performance-based compensation expense, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors, which management believes to be reasonable under the circumstances, including the current economic environment. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods.

Investments. We consider all investments to be available-for-sale securities. These securities are comprised of guaranteed investment certificates and corporate bonds with purchased maturities greater than ninety days. Available-for-sale securities are carried at fair value, based upon quoted market prices, with unrealized gains and losses, if any, reported in stockholders’ equity as a component of accumulated other comprehensive loss.

The following is a summary of our available-for-sale securities as of June 30, 2018 and December 31, 2017:

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
June 30, 2018
Guaranteed investment certificates	$	23,982	$	—	$	—		$	23,982
Corporate bonds		86,986		—		(871	)		86,115
Total available-for-sale securities	$	110,968	$	—	$	(871	)	$	110,097
December 31, 2017
Guaranteed investment certificates	$	22,261	$	—	$	—		$	22,261
Corporate bonds		82,010		—		(553	)		81,457
Total available-for-sale securities	$	104,271	$	—	$	(553	)	$	103,718
At June 30, 2018, maturities of our available-for-sale securities were as follows:
Less than one year	$	74,736	$	—	$	(467	)	$	74,269
Greater than one year	$	36,232	$	—	$	(404	)	$	35,828

Fair Value of Financial Instruments. As of June 30, 2018 and December 31, 2017, the carrying values of cash and cash equivalents, restricted cash, accounts receivable, and accounts payable approximate their respective fair values based on their short-term nature.

Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

All of our available-for-sale securities are measured as Level 1 instruments as of June 30, 2018 and December 31, 2017.

Included in cash and cash equivalents at June 30, 2018 and December 31, 2017, was $32,915 and $40,760 invested in government money market funds and certificates of deposit. Both are measured as Level 1 instruments.

We offer a nonqualified deferred compensation plan for certain eligible employees and members of our Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and Company stock. The fair value of the plan assets as of June 30, 2018 and December 31, 2017 was $5,010 and $3,514, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments. The fair value of plan assets is included in other assets with the same amount included in other liabilities in the accompanying consolidated balance sheets.

In 2018, we purchased a certificate of deposit (“CD”) from a commercial bank as collateral for a standby letter of credit. The CD bears an interest rate of 1.68% and matures on August 20, 2018. The carrying value of the CD approximates its fair value and is reported as restricted cash on the accompanying consolidated balance sheets. Also see Note 8 – Commitments and Contingencies.

Inventories. Inventories are stated at the lower of cost or net realizable value with cost determined on a first-in, first-out basis, and are comprised of the following:

	June 30, 2018		December 31, 2017
Raw materials	$	11,677	$	10,299
Work in process		284		199
Finished goods		8,638		8,845
	$	20,599	$	19,343

Property and Equipment. Property and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty to forty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold, retired, or discarded, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statements of operations. Accumulated depreciation of property and equipment as of June 30, 2018 and December 31, 2017 was $41,037 and $39,379, respectively.

Intangible Assets. Intangible assets consist of a customer list, patents and product rights, acquired technology and tradenames. Patents and product rights consist of costs associated with the acquisition of patents, licenses, and product distribution rights. Intangible assets are amortized using the straight-line method over their estimated useful lives of seven to fifteen years. Accumulated amortization of intangible assets as of June 30, 2018 and December 31, 2017 was $19,380 and $18,692, respectively. The change in intangibles from $8,223 as of December 31, 2017 to $6,622 as of June 30, 2018 is a result of $1,324 in amortization expense and $277 in foreign currency translation.

Goodwill. Goodwill represents the excess of the purchase price we paid over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in our acquisition of DNAG in August 2011. Goodwill is not amortized but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current U.S. generally accepted accounting principles permit us to make a qualitative evaluation about the likelihood of goodwill impairment. If we conclude that it is more likely than not that the carrying value of a reporting unit is greater than its fair value, then we would be required to recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value, provided the impairment charge does not exceed the total amount of goodwill allocated to the reporting unit.

We performed our last annual impairment assessment as of July 31, 2017 utilizing a qualitative evaluation and concluded that it was more likely than not that the fair value of our DNAG reporting unit is greater than its carrying value. We believe we have made reasonable estimates and assumptions to calculate the fair value of our reporting unit. If actual future results are not consistent with management’s estimates and assumptions, we may have to take an impairment charge in the future related to our goodwill. Future impairment tests will continue to be performed annually in the fiscal third quarter, or sooner if a triggering event occurs. As of June 30, 2018, we believe no indicators of impairment exist.

The decrease in goodwill from $20,083 as of December 31, 2017 to $19,231 as of June 30, 2018 is a result of foreign currency translation.

Earnings Per Share. Basic earnings per share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed in a manner similar to basic earnings per share except that the weighted-average number of shares outstanding is increased to include incremental shares from the assumed vesting or exercise of dilutive securities, such as common stock options, unvested restricted stock or performance stock units, unless the impact is antidilutive. The number of incremental shares is calculated by assuming that outstanding stock options were exercised and unvested restricted shares and performance stock units were vested, and the proceeds from such exercises or vesting were used to acquire shares of common stock at the average market price during the reporting period.

The computations of basic and diluted earnings per share are as follows:

	Three Months				Six Months
	Ended June 30,				Ended June 30,
	2018		2017		2018		2017
Net income	$	4,121	$	5,428	$	2,002	$	17,869
Weighted-average shares of common stock outstanding:
Basic		61,100		58,478		60,983		57,708
Dilutive effect of stock options, restricted stock, and performance stock units		1,144		2,250		1,396		2,047
Diluted		62,244		60,728		62,379		59,755
Earnings per share:
Basic	$	0.07	$	0.09	$	0.03	$	0.31
Diluted	$	0.07	$	0.09	$	0.03	$	0.30

For the three months ended June 30, 2018 and 2017, outstanding common stock options, unvested restricted stock, and unvested performance stock units representing 210 and 40 shares, respectively, were excluded from the computation of diluted earnings per share as their inclusion would have been anti-dilutive. For the six months ended June 30, 2018 and 2017, outstanding common stock options, unvested restricted stock, and unvested performance stock units representing 205 and 353 shares, respectively, were similarly excluded from the computation of diluted earnings per share.

Foreign Currency Translation. The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity.

Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than functional currency are included in our consolidated statements of income in the period in which the change occurs. Net foreign exchange gains (losses) resulting from foreign currency transactions that are included in other income (expense) in our consolidated statements of operations were $91 and ($418) for the three months ended June 30, 2018 and 2017, respectively. Net foreign exchange gains (losses) were $345 and ($618) for the six months ended June 30, 2018 and 2017, respectively.

Accumulated Other Comprehensive Income (Loss). We classify items of other comprehensive income (loss) by their nature and disclose the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our consolidated balance sheets.

We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and as such, the results of its operations are translated into U.S. dollars, which is the reporting currency of the Company. Accumulated other comprehensive loss at June 30, 2018 consists of $13,593 of currency translation adjustments and $871 of net unrealized losses on marketable securities, which represents the fair market value adjustment for our investment portfolio. Accumulated other comprehensive loss at December 31, 2017 consists of $9,787 of currency translation adjustments and $553 of net unrealized losses on marketable securities.

Recent Accounting Pronouncements. In February 2016, the FASB issued ASU 2016-02, Leases, which requires entities to begin recording assets and liabilities from leases on the balance sheet. The new guidance will also require significant additional disclosures about the amount, timing and uncertainty of cash flows from leases. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2018, using a modified retrospective approach. Early adoption is permitted. We are evaluating the effect that ASU 2016-02 may have on our consolidated financial statements and related disclosures.

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, which provides guidance related to cash flows presentation and is effective for annual reporting periods beginning after December 15, 2017, subject to early adoption. We adopted ASU 2016-15 on January 1, 2018 and this standard did not have a material impact on our consolidated financial statements.

In March 2017, the FASB issued ASU 2017-08, Receivables-Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities, which shortens the premium amortization period for purchased non-contingently callable debt securities. Shortening the amortization period is generally expected to more closely align the interest income recognition with the expectations incorporated in the market pricing of the underlying securities. This ASU is effective for annual and interim periods in fiscal years beginning after December 15, 2018. Early adoption is permitted. We adopted ASU 2017-08 on January 1, 2018 and this standard did not have a material impact on our consolidated financial statements.

In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting, to provide clarity to which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This update will be effective for annual periods and interim periods in fiscal years beginning after December 15, 2017 with early adoption permitted. We adopted ASU 2017-09 on January 1, 2018 and this standard did not have a material impact on our consolidated financial statements.

Revenues

6 Months Ended

Jun. 30, 2018

Revenue From Contract With Customer [Abstract]

Revenues

Adoption of New Revenue Recognition Standard

In January 2018, we adopted ASU 2014-09, Revenue from Contracts with Customers using the modified retrospective method applied to contracts existing as of January 1, 2018. Results for reporting periods beginning after January 1, 2018 are presented under the new guidance, while prior period amounts are not adjusted and continue to be reported in accordance with previous guidance.

Upon adoption, we recorded a reduction of $75 to the opening balance of accumulated deficit as of January 1, 2018. This adjustment is related to the change in revenue recognition associated with our drug testing kit sales. Sales of our drug testing kits include two performance obligations: sales of the device and laboratory services. Under this new accounting standard, we adjusted the allocation of the transaction price to the performance obligations and the estimate of unexercised rights (“breakage”) associated with the contracts. Prior to the adoption of the new guidance, we used the residual value method to allocate the transaction prices. With the adoption of ASU 2014-09, we allocated transition prices based upon the stand-alone selling price, or fair value method. This change in methodology also impacted our estimated breakage amount.

The following table summarizes the impact of the new revenue standard adjustment on our opening balance sheet:

	Balance at			New Revenue			Balance at
	December 31, 2017			Standard Adjustment			January 1, 2018
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Deferred revenue		1,314			75			1,389
STOCKHOLDERS' EQUITY
Accumulated deficit		(119,510	)		(75	)		(119,585	)

The adoption of this new standard had an immaterial impact on our reported total revenues and operating income, as compared to what would have been reported under the prior standard. We expect the impact of adoption in future periods to continue to be immaterial. Our accounting policies under the new standard were applied prospectively and are noted below.

Revenue Policies

Product sales. Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon delivery, based on an amount that reflects the consideration we are entitled to, net of allowances for any discounts or rebates.

Our net revenues recorded on sales of the OraQuick^® In-Home HIV test represent total gross revenues, less an allowance for expected returns, and customer allowances for cooperative advertising, discounts, rebates, and chargebacks. The allowance for expected returns is an estimate established by management, based upon currently available information, and is adjusted to reflect known changes in the factors that impact this estimate. Other customer allowances are at contractual rates and are recorded as a reduction of gross revenue when recognized in our consolidated statements of operations.

We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold.

Arrangements with multiple-performance obligations. In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or services is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on their respective relative stand-alone selling price. The estimated selling price of each deliverable reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis or using an adjusted market assessment approach if selling price on a stand-alone basis is not available. The consideration allocated to each distinct performance obligation is recognized as revenue when control is transferred for the related goods or services.

Other revenues. Other revenues consist primarily of royalty income, funding of research and development efforts and cost reimbursements under a charitable support agreement. Royalties from licensees are based on third-party sales of licensed products and are recorded when the related third-party product sale occurs. Funding and charitable support reimbursements are recorded as the activities are being performed in accordance with the respective agreements.

As part of our litigation settlement agreement with Ancestry.com DNA LLC (“Ancestry”) and its contract manufacturer, we granted Ancestry a royalty-bearing, non-exclusive, worldwide license to certain patents and patent applications related to the collection of DNA in human saliva. The license granted to Ancestry is limited to saliva DNA collection kits sold or used as part of Ancestry’s genetic testing service offerings and does not cover the sale or use of collection kits outside of Ancestry’s business. During the three and six months ended June 30, 2018, we recorded $2,092 and $3,694, respectively, in royalty income under this agreement.

On June 12, 2015, we were awarded a grant for up to $10,400 in total funding from the U.S. Department of Health and Human Services (“HHS”) Office of the Assistant Secretary for Preparedness and Response’s Biomedical Advanced Research and Development Authority (“BARDA”) related to our OraQuick^® Ebola rapid antigen test. The three-year, multi-phased grant, which expires in October 2018, included an initial commitment of $1,800 and options for up to an additional $8,600 to fund certain clinical and regulatory activities. In September 2015 and July 2017, BARDA exercised options to provide $7,200 and $1,330, respectively, in additional funding for our OraQuick^® Ebola test. Amounts related to this grant are recorded as other revenue in our consolidated statements of operations as the activities are being performed and the related costs are incurred. During the three and six months ended June 30, 2018, $962 and $1,799, respectively, were recognized in connection with this grant. During the three and six months ended June 30, 2017, $454 and $874, respectively, were recognized in connection with this grant.

In August 2016, we were awarded a contract for up to $16,600 in total funding from BARDA related to our rapid Zika test. The six-year, multi-phased contract includes an initial commitment of $7,000 and options for up to an additional $9,600 to fund the evaluation of additional product enhancements, and clinical and regulatory activities. In May 2017, BARDA exercised an option to provide $2,600 in additional funding for our rapid Zika test. Funding received under this contract is recorded as other revenue in our consolidated statements of operations as the activities are being performed and the related costs are incurred. During the three and six months ended June 30, 2018, $958 and $1,659, respectively, were recognized as other revenue in connection with this grant. During the three and six months ended June 30, 2017, $590 and $1,234, respectively, were recognized in connection with this grant.

In June 2017, we entered into a four-year Charitable Support Agreement with the Bill & Melinda Gates Foundation (“Gates Foundation”) that allows us to offer our OraQuick^® HIV self-test at an affordable price in 50 developing countries with funding from the Gates Foundation. The funding consists of support payments tied to volume of product sold by us and reimbursement of certain related costs. The funding from the Gates Foundation will be in an aggregate amount not to exceed $20,000 over the four-year term or $6,000 each year of the agreement. Funding received under this agreement in the form of support payments for product purchases is recorded as a component of product revenue. During the three and six months ended June 30, 2018, $1,709 and $2,732, respectively, of support payments were recognized in product revenue in connection with this agreement. Funding received in the form of reimbursement of certain related costs is recorded as other revenue in our consolidated statements of operations. During the three and six months ended June 30, 2018, $795 and $1,324, respectively, were recognized in other revenue for reimbursement of certain related costs. No funding was received during the three and six months ended June 30, 2017.

Deferred Revenue. We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of June 30, 2018 and December 31, 2017 includes customer prepayments of $1,263 and $1,045, respectively. Deferred revenue as of June 30, 2018 and December 31, 2017 also includes $358 and $269, respectively, associated with a long-term contract that has variable pricing based on volume. The average price over the life of the contract was determined and revenue is recognized at that rate.

Financing and Payment. Our payment terms vary by the type and location of our customer and products or services offered. Payment terms differ by jurisdiction and customer but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation.

For certain products or services and customer types, we may require payment before the products are delivered or services are rendered to the customer.

Practical expedients and exemptions. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues.

Other than for sales of our OraQuick^® In-Home HIV test to the retail trade, we do not grant product return rights to our customers except for warranty returns. Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, we expense warranty returns as incurred.

We do not grant return rights to our customers for any product, except for our OraQuick^® In-Home HIV test. Accordingly, we have recorded an estimate of expected returns as a reduction of gross OraQuick^® In-Home HIV product revenues in our consolidated statements of operations. This estimate reflects our historical sales experience to retailers and consumers, as well as other retail factors, and is reviewed regularly to ensure that it reflects potential product returns. As of June 30, 2018 and December 31, 2017, the reserve for sales returns and allowances was $197 and $217, respectively. If actual product returns differ materially from our reserve amount, or if a determination is made that this product’s distribution would be discontinued in whole or in part by certain retailers, then we would need to adjust our reserve. Should the actual level of product returns vary significantly from our estimates, our operating and financial results could be materially affected.

Sales commissions are expensed when incurred if the amortization period is one year or less. These costs are recorded in sales and marketing expense in the consolidated statements of operations. If the amortization period exceeds one year, we defer the cost of the commission and expense it over the life of the related sales contract.

Revenues by product. The following table represents total net revenues by product line:

	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
OraQuick®	$	15,791	$	16,530	$	28,796	$	30,639
Oragene®		15,368		15,215		32,456		25,154
Intercept®		2,154		2,239		4,069		4,166
Histofreezer®		1,973		2,570		4,327		5,250
Other products		3,532		2,578		7,488		5,405
Net product revenues		38,818		39,132		77,136		70,614

Royalty income		2,092		-		3,694		-
BARDA funding		1,920		1,044		3,458		2,108
Charitable support reimbursement		795		-		1,324		-
Other revenues		4,807		1,044		8,476		2,108

Net revenues	$	43,625	$	40,176	$	85,612	$	72,722

Revenues by geographic area. The following table represents total net revenues by geographic area, based on the location of the customer:

	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
United States	$	31,991	$	28,954	$	62,977	$	49,808
Europe		2,308		2,436		5,205		5,561
Other regions		9,326		8,786		17,430		17,353
	$	43,625	$	40,176	$	85,612	$	72,722

Customer and Vendor Concentrations. One of our customers accounted for 18% and 37% of our accounts receivable as of June 30, 2018 and December 31, 2017, respectively. The same customer accounted for approximately 18% and 21% of our net consolidated revenues for the three and six months ended June 30, 2018 and 20% and 15% of our net consolidated revenues for the three and six months ended June 30, 2017. Another customer accounted for 10% of our net consolidated revenues for the three months ended June 30, 2017.

We currently purchase certain products and critical components of our products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Also, our subsidiary, DNAG, uses two third-party suppliers to manufacture its products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations.

Accrued Expenses

6 Months Ended

Jun. 30, 2018

Payables And Accruals [Abstract]

Accrued Expenses

4.	Accrued Expenses

	June 30, 2018		December 31, 2017
Payroll and related benefits	$	4,949	$	9,265
Income taxes payable		—		6,469
Professional fees		1,211		1,064
Royalties		1,054		845
Other		2,623		3,052
	$	9,837	$	20,695

Credit Facility

6 Months Ended

Jun. 30, 2018

Debt Disclosure [Abstract]

Credit Facility

5.	Credit Facility

On September 30, 2016, we entered into a credit agreement (the “Credit Agreement”) with a commercial bank. The Credit Agreement, as amended on December 20, 2017, provides for revolving extensions of credit in an initial aggregate amount of up to $10,000 (inclusive of a letter of credit subfacility of $2,500), with an option to request, prior to the second anniversary of the closing date, that the lender, at its election, provide up to $5,000 of additional revolving commitments. Obligations under the Credit Agreement are secured by a first priority security interest in certain eligible accounts receivable, 65% of the equity of our subsidiary, DNAG, and certain related assets. There were no borrowings outstanding under the facility at June 30, 2018 and December 31, 2017.

Borrowings under the Credit Agreement are subject to compliance with borrowing base limitations tied to eligibility of accounts receivable. Interest under the Credit Agreement is payable at the London Interbank Offered Rate for one, two, three or six-month loans, as selected by the Company, plus 2.50% per year. The Credit Agreement is subject to an unused line fee of 0.375% per year on the unused portion of the commitment under the Credit Agreement during the revolving period. The maturity date of the Credit Agreement is September 30, 2019.

In connection with the Credit Agreement, under certain circumstances, we must comply with a minimum fixed charge coverage ratio of 1.10 to 1.00, measured as of the last day of each fiscal month and for the twelve-fiscal month period ending on such date. As of June 30, 2018 and December 31, 2017, we were in compliance with all applicable covenants in the Credit Agreement.

Stockholders' Equity

6 Months Ended

Jun. 30, 2018

Equity [Abstract]

Stockholders' Equity

6.	Stockholders’ Equity

Stock-Based Awards

We grant stock-based awards under the OraSure Technologies, Inc. Stock Award Plan, as amended (the “Stock Plan”). The Stock Plan permits stock-based awards to employees, outside directors and consultants or other third-party advisors. Awards which may be granted under the Stock Plan include qualified incentive stock options, nonqualified stock options, stock appreciation rights, restricted awards, performance awards and other stock-based awards. We recognize compensation expense for stock option and restricted stock awards issued to employees and directors on a straight-line basis over the requisite service period of the award. We recognize compensation expense related to performance-based restricted stock units based on assumptions as to what percentage of each performance target will be achieved. We evaluate these target assumptions on a quarterly basis and adjust compensation expense related to these awards, as appropriate. To satisfy the exercise of options or to issue restricted stock, or redeem performance-based restricted stock units, we issue new shares rather than purchase shares on the open market.

Total compensation cost related to stock options for the six months ended June 30, 2018 and 2017 was $1,375 and $1,007, respectively. Net cash proceeds from the exercise of stock options were $1,201 and $21,014 for the six months ended June 30, 2018 and 2017, respectively. As a result of our net operating loss carryforward position, no actual income tax benefit was realized from stock option exercises during these periods.

Compensation cost of $5,045 and $1,355 related to restricted shares was recognized during the six months ended June 30, 2018 and 2017, respectively. In connection with the vesting of restricted shares during the six months ended June 30, 2018 and 2017, we purchased and immediately retired 163 and 120 shares with aggregate values of $3,171 and $1,209, respectively, in satisfaction of minimum tax withholding obligations.

We grant performance-based restricted stock units (“PSUs”) to certain executives. Vesting of these PSUs is dependent upon achievement of performance-based metrics during a one-year or three-year period, from the date of grant. Assuming achievement of each performance-based metric, the executive must also remain in our service for three years from the grant date. Performance during the one-year period is based on a one-year earnings per share or income before income taxes target. If the one-year target is achieved, the PSUs will then vest three years from grant date. Performance during the three-year period will be based on achievement of a three-year compound annual growth rate for consolidated product revenues. If the three-year target is achieved, the corresponding PSUs will then vest three years from grant date. PSUs are converted into shares of our common stock once vested. Upon grant of the PSUs, we recognize compensation expense related to these awards based on assumptions as to what percentage of each target will be achieved. The Company evaluates these target assumptions on a quarterly basis and adjusts compensation expense related to these awards, as appropriate.

Compensation cost of $4,842 and $1,269 related to PSUs was recognized during the six months ended June 30, 2018 and 2017, respectively.

Modification of Grants

Stock compensation costs for the three and six months ended June 30, 2018 include the additional expense associated with modifications of existing grants held by our retiring President and Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”). These additional costs were $2,188 and $8,039 during the three and six months ended June 30, 2018, respectively.

Stock Repurchase Program

On August 5, 2008, our Board of Directors approved a share repurchase program pursuant to which we are permitted to acquire up to $25,000 of our outstanding common shares. No shares were purchased and retired during the six months ended June 30, 2018 and 2017.

Income Taxes

6 Months Ended

Jun. 30, 2018

Income Tax Disclosure [Abstract]

Income Taxes

7.	Income Taxes

During the three and six months ended June 30, 2018, we recorded tax expense of $2,173 and $4,206, respectively. During the three and six months ended June 30, 2017, we recorded tax expense of $1,555 and $5,452, respectively.

Tax expense reflects taxes due to Canadian taxing authorities and the tax effects of temporary differences between the basis of assets and liabilities recognized for financial reporting and tax purposes, and net operating loss and tax credit carryforwards. Tax expense in the first six months of 2017 also includes the additional Canadian taxes due as a result of the $12,500 gain from the settlement of our patent infringement and breach of contract litigation against Ancestry.com DNA LLC and its contract manufacturer.

The significant components of our total deferred tax liability as of June 30, 2018 and December 31, 2017 relate to the tax effects of the basis difference between the intangible assets acquired in the DNAG acquisition for financial reporting and tax purposes.

In 2008, we established a full valuation allowance against our U.S. deferred tax asset. Management believes the full valuation allowance is still appropriate at both June 30, 2018 and December 31, 2017 since the facts and circumstances necessitating the allowance have not changed. As a result, no U.S. federal or state deferred income tax expense or benefit was recorded for the three and six-month periods ended June 30, 2018 and 2017.

On December 22, 2017, the U.S. enacted the Tax Cuts and Jobs Act (“Tax Act”) that instituted fundamental changes to the taxation on multinational corporations. Provisions of the Tax Act, which was effective January 1, 2018, include a permanent reduction in the corporate tax rate to 21% and a one-time transition tax imposed on a U.S. shareholder’s historical undistributed earnings of foreign affiliates. Given that the U.S. entity has a full valuation allowance against its deferred tax assets and is generating net operating losses (“NOLs”), these tax provisions do not impact our financial results.

The Tax Act also imposes a U.S. tax on global intangible low taxed income (“GILTI”) that is earned by certain foreign affiliates owned by a U.S. shareholder effective in 2018. GILTI is generally intended to impose tax on the earnings of a foreign corporation that are deemed to exceed a certain threshold return relative to the underlying tangible property. Although we are subject to GILTI, the computation of GILTI is still subject to interpretation and additional clarifying guidance is expected. Tax law ordering rules require that NOLs be utilized first to offset any GILTI tax liability before the use of any other tax attributes. We have sufficient NOLs to offset our projected 2018 GILTI income inclusion.

As a result of the complex impact of the Tax Act, the SEC provided guidance under Staff Accounting Bulletin No. 118 (“SAB 118”) that allows the Company to record provisional amounts as of December 31, 2017 for the impact of the Tax Act, provided that the provisional amounts can be reasonably determined and with the requirement that the final accounting be completed in a period not to exceed one year from the date of enactment. During the three and six months ended June 30, 2018, there were no adjustments made to the provisional amounts that were recorded under SAB 118 as of December 31, 2017 and these amounts remain provisional at June 30, 2018.

Commitments and Contingencies

6 Months Ended

Jun. 30, 2018

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

8.	Commitments and Contingencies

Standby Letters of Credit

We issued a standby letter of credit in the amount of $22, naming an international customer as the beneficiary. This letter of credit was required as a performance guarantee of our obligations under our product supply contract with this customer and is collateralized by a certificate of deposit maintained at a commercial bank. The standby letter of credit is recorded in restricted cash in the accompanying consolidated balance sheets.

Litigation

From time to time, we are involved in certain legal actions arising in the ordinary course of business. In management’s opinion, the outcomes of such actions, either individually or in the aggregate, are not expected to have a material adverse effect on our future financial position or results of operations.

Transition Costs

6 Months Ended

Jun. 30, 2018

Transition Costs [Abstract]

Transition Costs

9.	Transition Costs

In January 2018, we announced the retirement of our President and CEO and our CFO and Chief Operating Officer. Stephen S. Tang, Ph.D., who served as Chairman of the Board of Directors (the “Board”), was appointed as the Company’s new President and CEO, effective as of April 1, 2018. Dr. Tang replaced Douglas A. Michels, who retired as President and CEO, and as a member of the Board, on March 31, 2018. In addition, Roberto Cuca was appointed as the Company’s new CFO, effective June 8, 2018. Mr. Cuca replaced Ronald H. Spair, our former CFO and Chief Operating Officer, who retired on that same date. Charges associated with these transitions were $2,188 and $8,628 during the three and six months ended June 30, 2018, respectively. These charges primarily reflect non-cash charges associated with modifications to existing stock grants held by the retiring executives and expenses associated with the onboarding of the Company’s new President and CEO.

Business Segment Information

6 Months Ended

Jun. 30, 2018

Segment Reporting [Abstract]

Business Segment Information

10.	Business Segment Information

We organized our operating segments according to the nature of the products included in those segments. The accounting policies of the segments are the same as those described in the summary of significant accounting policies (see Note 2). We evaluate performance of our operating segments based on revenue and operating income. We do not allocate interest income, interest expense, other income, other expenses or income taxes to our operating segments. Reportable segments have no inter-segment revenues and inter-segment expenses have been eliminated.

The following table summarizes operating segment information for the three and six months ended June 30, 2018 and 2017, and asset information as of June 30, 2018 and December 31, 2017:

	Three Months Ended June 30,					Six Months Ended June 30,
	2018			2017		2018			2017
Net revenues:
OSUR	$	24,341		$	24,119	$	46,365		$	45,958
DNAG		19,284			16,057		39,247			26,764
Total	$	43,625		$	40,176	$	85,612		$	72,722
Operating income (loss):
OSUR	$	(2,922	)	$	438	$	(11,821	)	$	218
DNAG		8,480			6,449		16,881			22,540
Total	$	5,558		$	6,887	$	5,060		$	22,758
Depreciation and amortization:
OSUR	$	993		$	678	$	2,004		$	1,334
DNAG		885			793		1,742			1,557
Total	$	1,878		$	1,471	$	3,746		$	2,891
Capital expenditures:
OSUR	$	1,358		$	553	$	2,774		$	1,337
DNAG		1,229			136		1,710			230
Total	$	2,587		$	689	$	4,484		$	1,567

	June 30, 2018		December 31, 2017
Total assets:
OSUR	$	188,426	$	192,352
DNAG		103,936		103,849
Total	$	292,362	$	296,201

The following table represents total long-lived assets by geographic area:

	June 30, 2018		December 31, 2017
United States	$	17,720	$	16,160
Canada		6,080		5,083
Other regions		146		129
	$	23,946	$	21,372

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2018

Accounting Policies [Abstract]

Principles of Consolidation and Basis of Presentation

Use of Estimates

Investments

The following is a summary of our available-for-sale securities as of June 30, 2018 and December 31, 2017:

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
June 30, 2018
Guaranteed investment certificates	$	23,982	$	—	$	—		$	23,982
Corporate bonds		86,986		—		(871	)		86,115
Total available-for-sale securities	$	110,968	$	—	$	(871	)	$	110,097
December 31, 2017
Guaranteed investment certificates	$	22,261	$	—	$	—		$	22,261
Corporate bonds		82,010		—		(553	)		81,457
Total available-for-sale securities	$	104,271	$	—	$	(553	)	$	103,718
At June 30, 2018, maturities of our available-for-sale securities were as follows:
Less than one year	$	74,736	$	—	$	(467	)	$	74,269
Greater than one year	$	36,232	$	—	$	(404	)	$	35,828

Fair Value of Financial Instruments

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

All of our available-for-sale securities are measured as Level 1 instruments as of June 30, 2018 and December 31, 2017.

Inventories

Inventories. Inventories are stated at the lower of cost or net realizable value with cost determined on a first-in, first-out basis, and are comprised of the following:

	June 30, 2018		December 31, 2017
Raw materials	$	11,677	$	10,299
Work in process		284		199
Finished goods		8,638		8,845
	$	20,599	$	19,343

Property and Equipment

Intangible Assets

Goodwill

The decrease in goodwill from $20,083 as of December 31, 2017 to $19,231 as of June 30, 2018 is a result of foreign currency translation.

Earnings Per Share

The computations of basic and diluted earnings per share are as follows:

	Three Months				Six Months
	Ended June 30,				Ended June 30,
	2018		2017		2018		2017
Net income	$	4,121	$	5,428	$	2,002	$	17,869
Weighted-average shares of common stock outstanding:
Basic		61,100		58,478		60,983		57,708
Dilutive effect of stock options, restricted stock, and performance stock units		1,144		2,250		1,396		2,047
Diluted		62,244		60,728		62,379		59,755
Earnings per share:
Basic	$	0.07	$	0.09	$	0.03	$	0.31
Diluted	$	0.07	$	0.09	$	0.03	$	0.30

Foreign Currency Translation

Accumulated Other Comprehensive Income (Loss)

Recent Accounting Pronouncements

Product Sales

We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold.

Arrangements with Multiple-performance Obligations

Other Revenues

Deferred Revenue

Financing and Payment

For certain products or services and customer types, we may require payment before the products are delivered or services are rendered to the customer.

Practical Expedients and Exemptions

Practical expedients and exemptions. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues.

Revenues by Product

Revenues by product. The following table represents total net revenues by product line:

	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
OraQuick®	$	15,791	$	16,530	$	28,796	$	30,639
Oragene®		15,368		15,215		32,456		25,154
Intercept®		2,154		2,239		4,069		4,166
Histofreezer®		1,973		2,570		4,327		5,250
Other products		3,532		2,578		7,488		5,405
Net product revenues		38,818		39,132		77,136		70,614

Royalty income		2,092		-		3,694		-
BARDA funding		1,920		1,044		3,458		2,108
Charitable support reimbursement		795		-		1,324		-
Other revenues		4,807		1,044		8,476		2,108

Net revenues	$	43,625	$	40,176	$	85,612	$	72,722

Revenues by Geographic Area

Revenues by geographic area. The following table represents total net revenues by geographic area, based on the location of the customer:

	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
United States	$	31,991	$	28,954	$	62,977	$	49,808
Europe		2,308		2,436		5,205		5,561
Other regions		9,326		8,786		17,430		17,353
	$	43,625	$	40,176	$	85,612	$	72,722

Customer and Vendor Concentrations

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2018

Accounting Policies [Abstract]

Summary of Available-for-sale Securities

The following is a summary of our available-for-sale securities as of June 30, 2018 and December 31, 2017:

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
June 30, 2018
Guaranteed investment certificates	$	23,982	$	—	$	—		$	23,982
Corporate bonds		86,986		—		(871	)		86,115
Total available-for-sale securities	$	110,968	$	—	$	(871	)	$	110,097
December 31, 2017
Guaranteed investment certificates	$	22,261	$	—	$	—		$	22,261
Corporate bonds		82,010		—		(553	)		81,457
Total available-for-sale securities	$	104,271	$	—	$	(553	)	$	103,718
At June 30, 2018, maturities of our available-for-sale securities were as follows:
Less than one year	$	74,736	$	—	$	(467	)	$	74,269
Greater than one year	$	36,232	$	—	$	(404	)	$	35,828

Schedule of Inventories

Inventories are stated at the lower of cost or net realizable value with cost determined on a first-in, first-out basis, and are comprised of the following:

	June 30, 2018		December 31, 2017
Raw materials	$	11,677	$	10,299
Work in process		284		199
Finished goods		8,638		8,845
	$	20,599	$	19,343

Computations of Basic and Diluted Earnings Per Share

The computations of basic and diluted earnings per share are as follows:

	Three Months				Six Months
	Ended June 30,				Ended June 30,
	2018		2017		2018		2017
Net income	$	4,121	$	5,428	$	2,002	$	17,869
Weighted-average shares of common stock outstanding:
Basic		61,100		58,478		60,983		57,708
Dilutive effect of stock options, restricted stock, and performance stock units		1,144		2,250		1,396		2,047
Diluted		62,244		60,728		62,379		59,755
Earnings per share:
Basic	$	0.07	$	0.09	$	0.03	$	0.31
Diluted	$	0.07	$	0.09	$	0.03	$	0.30

Revenues (Tables)

6 Months Ended

Jun. 30, 2018

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Disaggregation of Revenue by Product and Geographic Area

Revenues by product. The following table represents total net revenues by product line:

	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
OraQuick®	$	15,791	$	16,530	$	28,796	$	30,639
Oragene®		15,368		15,215		32,456		25,154
Intercept®		2,154		2,239		4,069		4,166
Histofreezer®		1,973		2,570		4,327		5,250
Other products		3,532		2,578		7,488		5,405
Net product revenues		38,818		39,132		77,136		70,614

Royalty income		2,092		-		3,694		-
BARDA funding		1,920		1,044		3,458		2,108
Charitable support reimbursement		795		-		1,324		-
Other revenues		4,807		1,044		8,476		2,108

Net revenues	$	43,625	$	40,176	$	85,612	$	72,722

Revenues by geographic area. The following table represents total net revenues by geographic area, based on the location of the customer:

	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
United States	$	31,991	$	28,954	$	62,977	$	49,808
Europe		2,308		2,436		5,205		5,561
Other regions		9,326		8,786		17,430		17,353
	$	43,625	$	40,176	$	85,612	$	72,722

ASU 2014-09 [Member]

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Summary of Impact of New Revenue Standard Adjustment on Opening Balance Sheet

The following table summarizes the impact of the new revenue standard adjustment on our opening balance sheet:

	Balance at			New Revenue			Balance at
	December 31, 2017			Standard Adjustment			January 1, 2018
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Deferred revenue		1,314			75			1,389
STOCKHOLDERS' EQUITY
Accumulated deficit		(119,510	)		(75	)		(119,585	)

Accrued Expenses (Tables)

6 Months Ended

Jun. 30, 2018

Payables And Accruals [Abstract]

Schedule of Accrued Expenses

	June 30, 2018		December 31, 2017
Payroll and related benefits	$	4,949	$	9,265
Income taxes payable		—		6,469
Professional fees		1,211		1,064
Royalties		1,054		845
Other		2,623		3,052
	$	9,837	$	20,695

Business Segment Information (Tables)

6 Months Ended

Jun. 30, 2018

Segment Reporting [Abstract]

Summary of Operating Segment and Asset Information

The following table summarizes operating segment information for the three and six months ended June 30, 2018 and 2017, and asset information as of June 30, 2018 and December 31, 2017:

	Three Months Ended June 30,					Six Months Ended June 30,
	2018			2017		2018			2017
Net revenues:
OSUR	$	24,341		$	24,119	$	46,365		$	45,958
DNAG		19,284			16,057		39,247			26,764
Total	$	43,625		$	40,176	$	85,612		$	72,722
Operating income (loss):
OSUR	$	(2,922	)	$	438	$	(11,821	)	$	218
DNAG		8,480			6,449		16,881			22,540
Total	$	5,558		$	6,887	$	5,060		$	22,758
Depreciation and amortization:
OSUR	$	993		$	678	$	2,004		$	1,334
DNAG		885			793		1,742			1,557
Total	$	1,878		$	1,471	$	3,746		$	2,891
Capital expenditures:
OSUR	$	1,358		$	553	$	2,774		$	1,337
DNAG		1,229			136		1,710			230
Total	$	2,587		$	689	$	4,484		$	1,567

	June 30, 2018		December 31, 2017
Total assets:
OSUR	$	188,426	$	192,352
DNAG		103,936		103,849
Total	$	292,362	$	296,201

Presentation of Total Net Revenues and Long-Lived Assets by Geographic Area

The following table represents total long-lived assets by geographic area:

	June 30, 2018		December 31, 2017
United States	$	17,720	$	16,160
Canada		6,080		5,083
Other regions		146		129
	$	23,946	$	21,372

The Company - Additional Information (Detail)	6 Months Ended
The Company - Additional Information (Detail)	Jun. 30, 2018 Segment
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Number of Segments of company	2

Summary of Significant Accounting Policies - Summary of Available-for-sale Securities (Detail) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 110,968	$ 104,271
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(871)	(553)
Fair Value	110,097	103,718
Guaranteed Investment Certificates [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	23,982	22,261
Gross Unrealized Gains	0	0
Fair Value	23,982	22,261
Corporate Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	86,986	82,010
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(871)	(553)
Fair Value	86,115	$ 81,457
Less Than One Year [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	74,736
Gross Unrealized Gains	0
Gross Unrealized Losses	(467)
Fair Value	74,269
Greater Than One Year [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	36,232
Gross Unrealized Gains	0
Gross Unrealized Losses	(404)
Fair Value	$ 35,828

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cash and cash equivalents	$ 71,047		$ 71,047		$ 71,029
Fair value of plan assets	5,010		5,010		3,514
Accumulated depreciation of property and equipment	41,037		41,037		39,379
Accumulated amortization of intangible assets	19,380		19,380		18,692
Intangible Assets, Net	6,622		6,622		8,223
Intangible Assets, Accumulated Amortization			1,324
Intangible Assets, Foreign currency translation			277
Amount of goodwill at period end	19,231		19,231		20,083
Net foreign exchange gains (losses)	91	$ (418)	345	$ (618)
Accumulated foreign currency adjustments included in other comprehensive loss amounted	13,593		13,593		9,787
Unrealized loss on marketable securities	$ 871		$ 871		553
Common Stock Options Unvested Restricted Stock and Unvested Performance Units [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of anti-dilutive securities excluded from EPS computation	210	40	205	353
Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Useful life of Intangible assets			7 years
Minimum [Member] \| Buildings [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets			20 years
Minimum [Member] \| Computer Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets			2 years
Minimum [Member] \| Machinery and Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets			2 years
Minimum [Member] \| Furniture and Fixtures [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets			2 years
Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Useful life of Intangible assets			15 years
Maximum [Member] \| Buildings [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets			40 years
Maximum [Member] \| Computer Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets			10 years
Maximum [Member] \| Machinery and Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets			10 years
Maximum [Member] \| Furniture and Fixtures [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets			10 years
Certificates of Deposit [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Interest rate on certificate of deposit			1.68%
Certificate of deposit maturity date			Aug. 20, 2018
Money Market Fund [Member] \| Certificates of Deposit [Member] \| Level I Instruments [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cash and cash equivalents	$ 32,915		$ 32,915		$ 40,760

Summary of Significant Accounting Policies - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Inventory Net [Abstract]
Raw materials	$ 11,677	$ 10,299
Work in process	284	199
Finished goods	8,638	8,845
Inventories	$ 20,599	$ 19,343

Summary of Significant Accounting Policies - Computations of Basic and Diluted Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Earnings Per Share [Abstract]
Net income	$ 4,121	$ 5,428	$ 2,002	$ 17,869
Weighted-average shares of common stock outstanding:
Basic	61,100	58,478	60,983	57,708
Dilutive effect of stock options, restricted stock, and performance stock units	1,144	2,250	1,396	2,047
Diluted	62,244	60,728	62,379	59,755
Basic	$ 0.07	$ 0.09	$ 0.03	$ 0.31
Diluted	$ 0.07	$ 0.09	$ 0.03	$ 0.30

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Revenues - Additional Information (Detail)		1 Months Ended					3 Months Ended		6 Months Ended		12 Months Ended
Revenues - Additional Information (Detail)	Jun. 12, 2015 USD ($)	Jul. 31, 2017 USD ($)	Jun. 30, 2017 USD ($) Country	May 31, 2017 USD ($)	Aug. 31, 2016 USD ($)	Sep. 30, 2015 USD ($)	Jun. 30, 2018 USD ($) Supplier	Jun. 30, 2017 USD ($)	Jun. 30, 2018 USD ($) Supplier	Jun. 30, 2017 USD ($)	Dec. 31, 2017 USD ($)	Jan. 01, 2018 USD ($) PerformanceObligation
Revenue from contract with customer [Line Items]
Accumulated deficit							$ (117,583,000)		$ (117,583,000)		$ (119,510,000)
Maximum value of grant revenue from clinical and regulatory activities	$ 10,400,000				$ 16,600,000
Period of grant	3 years				6 years
Grant expiration period	2018-10
Initial grant revenue from clinical and regulatory activities	$ 1,800,000				$ 7,000,000
Remaining grant revenue from clinical and regulatory activities	$ 8,600,000				$ 9,600,000
Additional contract revenue from clinical and regulatory activities		$ 1,330,000		$ 2,600,000		$ 7,200,000
Contract revenues from clinical and regulatory activities							962,000	$ 454,000	1,799,000	$ 874,000
Deferred revenue							$ 1,621,000		$ 1,621,000		1,314,000
Contract with customer payment terms, description									Payment terms differ by jurisdiction and customer but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation.
Reserve for sales return and allowances									$ 197,000		$ 217,000
Customer [Member] \| Accounts Receivable [Member] \| Customer Concentration Risk [Member]
Revenue from contract with customer [Line Items]
Percentage of concentration risk									18.00%		37.00%
Customer [Member] \| Net Consolidated Revenue [Member] \| Customer Concentration Risk [Member]
Revenue from contract with customer [Line Items]
Percentage of concentration risk							18.00%	20.00%	21.00%	15.00%
Customer One [Member] \| Net Consolidated Revenue [Member] \| Customer Concentration Risk [Member]
Revenue from contract with customer [Line Items]
Percentage of concentration risk								10.00%
Minimum [Member]
Revenue from contract with customer [Line Items]
Contract with customer payment terms minimum									30 days
Maximum [Member]
Revenue from contract with customer [Line Items]
Contract with customer payment terms minimum									120 days
Sales commissions amortization period									1 year
Long-term Contract [Member]
Revenue from contract with customer [Line Items]
Deferred revenue							$ 358,000		$ 358,000		$ 269,000
Up Front Payment Arrangement [Member]
Revenue from contract with customer [Line Items]
Deferred revenue							1,263,000		1,263,000		$ 1,045,000
Other [Member]
Revenue from contract with customer [Line Items]
Contract revenues from clinical and regulatory activities							958,000	$ 590,000	1,659,000	$ 1,234,000
Ancestry.com DNA LLC [Member] \| Litigation Settlement Agreement [Member]
Revenue from contract with customer [Line Items]
Royalty income							$ 2,092,000		$ 3,694,000
DNA Genotek [Member]
Revenue from contract with customer [Line Items]
Number of third-party suppliers to manufacture DNAG's products \| Supplier							2		2
Ora Quick HIV Self Test [Member] \| Bill & Melinda Gates Foundation [Member]
Revenue from contract with customer [Line Items]
Charitable support agreement term			4 years
Number of countries in which products are sold \| Country			50
Maximum amount of funding over the agreement period			$ 20,000,000
Funding received per year			$ 6,000,000					$ 0		$ 0
Support payments recognized in product revenue							$ 1,709,000		$ 2,732,000
Support payments recognized in other revenue							$ 795,000		$ 1,324,000
Charitable support agreement commencement date									2017-06
ASU 2014-09 [Member]
Revenue from contract with customer [Line Items]
Accumulated deficit												$ (119,585,000)
Deferred revenue												$ 1,389,000
ASU 2014-09 [Member] \| Drug Testing Kit Sales [Member]
Revenue from contract with customer [Line Items]
Number of performance obligations \| PerformanceObligation												2
ASU 2014-09 [Member] \| Change in Revenue Recognition [Member]
Revenue from contract with customer [Line Items]
Accumulated deficit												$ (75,000)
Deferred revenue												75,000
ASU 2014-09 [Member] \| Change in Revenue Recognition [Member] \| Drug Testing Kit Sales [Member]
Revenue from contract with customer [Line Items]
Accumulated deficit												$ 75,000

Revenues - Summary of Impact of New Revenue Standard Adjustment on Opening Balance Sheet (Detail) - USD ($) $ in Thousands	Jun. 30, 2018	Jan. 01, 2018	Dec. 31, 2017
CURRENT LIABILITIES:
Deferred revenue	$ 1,621		$ 1,314
STOCKHOLDERS' EQUITY
Accumulated deficit	$ (117,583)		$ (119,510)
ASU 2014-09 [Member]
CURRENT LIABILITIES:
Deferred revenue		$ 1,389
STOCKHOLDERS' EQUITY
Accumulated deficit		(119,585)
New Revenue Standard Adjustment [Member] \| ASU 2014-09 [Member]
CURRENT LIABILITIES:
Deferred revenue		75
STOCKHOLDERS' EQUITY
Accumulated deficit		$ (75)

Revenues - Summary of Total Net Revenues by Product Line (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Disaggregation Of Revenue [Line Items]
Net revenues	$ 43,625	$ 40,176	$ 85,612	$ 72,722
Product Revenues [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	38,818	39,132	77,136	70,614
Product Revenues [Member] \| OraQuick [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	15,791	16,530	28,796	30,639
Product Revenues [Member] \| Oragene [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	15,368	15,215	32,456	25,154
Product Revenues [Member] \| Intercept [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	2,154	2,239	4,069	4,166
Product Revenues [Member] \| Histofreezer [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	1,973	2,570	4,327	5,250
Product Revenues [Member] \| Other Products [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	3,532	2,578	7,488	5,405
Other [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	4,807	1,044	8,476	2,108
Other [Member] \| Royalty Income [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	2,092		3,694
Other [Member] \| BARDA Funding [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	1,920	$ 1,044	3,458	$ 2,108
Other [Member] \| Charitable Support Reimbursement [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	$ 795		$ 1,324

Revenues - Summary of Total Net Revenues by Geographic Area (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Disaggregation Of Revenue [Line Items]
Net revenues	$ 43,625	$ 40,176	$ 85,612	$ 72,722
United States [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	31,991	28,954	62,977	49,808
Europe [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	2,308	2,436	5,205	5,561
Other Regions [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	$ 9,326	$ 8,786	$ 17,430	$ 17,353

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Accrued Liabilities Current [Abstract]
Payroll and related benefits	$ 4,949	$ 9,265
Income taxes payable		6,469
Professional fees	1,211	1,064
Royalties	1,054	845
Other	2,623	3,052
Accrued Expenses, Total	$ 9,837	$ 20,695

Credit Facility - Additional Information (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Line of Credit Facility [Line Items]
Current borrowing capacity	$ 10,000,000
Line of credit facility, collateral	Obligations under the Credit Agreement are secured by a first priority security interest in certain eligible accounts receivable, 65% of the equity of our subsidiary, DNAG, and certain related assets.
Borrowings	$ 0	$ 0
Unused capacity commitment fee	0.375%
Maturity date of credit facility	Sep. 30, 2019
Maximum [Member]
Line of Credit Facility [Line Items]
Additional revolving commitments	$ 5,000,000
Letter of Credit [Member]
Line of Credit Facility [Line Items]
Current borrowing capacity	$ 2,500,000
Line of Credit [Member]
Line of Credit Facility [Line Items]
Minimum fixed charge coverage ratio	110.00%
Line of Credit [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Line of Credit Facility [Line Items]
Line of credit, interest rate	2.50%

Stockholders' Equity - Additional Information (Detail) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2018	Jun. 30, 2017	Aug. 05, 2008
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost		$ 11,262,000	$ 3,631,000
Proceeds from exercise of stock options		1,201,000	21,014,000
Income tax benefit realized from stock option exercises during period		0	0
Amount share repurchase program of common shares				$ 25,000,000
Retiring President and Chief Executive Officer and Chief Financial Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	$ 2,188,000	8,039,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost		1,375,000	1,007,000
Proceeds from exercise of stock options		1,201,000	21,014,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost		$ 5,045,000	$ 1,355,000
Vesting of restricted shares and exercise of stock options, withholding and exercise obligations		163,000	120,000
Restricted shares of common stock and stock options, aggregate values		$ 3,171,000	$ 1,209,000
Performance Based Restricted Stock Unit [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost		$ 4,842,000	$ 1,269,000
Performance Based Restricted Stock [Member] \| Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		1 year
Performance Based Restricted Stock [Member] \| Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		3 years
Share Repurchase Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares purchased and retired		0	0

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Income tax expense	$ 2,173,000	$ 1,555,000	$ 4,206,000	$ 5,452,000
Gain from settlement of litigation against Ancestry.com DNA LLC				12,500,000
U.S. federal or state deferred income tax expense or benefits	$ 0	$ 0	$ 0	$ 0
Effective income tax rate			21.00%

Commitments and Contingencies - Additional Information (Detail) $ in Thousands	Jun. 30, 2018 USD ($)
Standby Letters of Credit [Member]
Contractual Obligation Fiscal Year Maturity [Line Items]
Standby letters of credit	$ 22

Transition Costs - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2018
Transition Costs [Abstract]
Non-cash charges associated with modifications to existing stock grants held by the retiring executives and expenses associated with the onboarding of the Company's new President and CEO	$ 2,188	$ 8,628

Business Segment Information - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2018 Segment
Segment Reporting [Abstract]
Number of reportable segments of company	2

Business Segment Information - Summary of Operating Segment and Asset Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Segment Reporting Information [Line Items]
Net revenues	$ 43,625	$ 40,176	$ 85,612	$ 72,722
Operating income (loss)	5,558	6,887	5,060	22,758
Depreciation and amortization	1,878	1,471	3,746	2,891
Capital expenditures	2,587	689	4,484	1,567
Total assets	292,362		292,362		$ 296,201
OSUR [Member]
Segment Reporting Information [Line Items]
Net revenues	24,341	24,119	46,365	45,958
Operating income (loss)	(2,922)	438	(11,821)	218
Depreciation and amortization	993	678	2,004	1,334
Capital expenditures	1,358	553	2,774	1,337
Total assets	188,426		188,426		192,352
DNAG [Member]
Segment Reporting Information [Line Items]
Net revenues	19,284	16,057	39,247	26,764
Operating income (loss)	8,480	6,449	16,881	22,540
Depreciation and amortization	885	793	1,742	1,557
Capital expenditures	1,229	$ 136	1,710	$ 230
Total assets	$ 103,936		$ 103,936		$ 103,849

Business Segment Information - Presentation of Total Net Revenues and Long-Lived Assets by Geographic Area (Detail) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	$ 23,946	$ 21,372
United States [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	17,720	16,160
Canada [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	6,080	5,083
Other Regions [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	$ 146	$ 129